Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) announced that CEO Sean P. Bohen, M.D., Ph.D. will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 2:30 p.m. ET. A live webcast and recording will be available on Olema’s investor relations site, subject to event host permissions.
Positive
- None.
Negative
- None.
News Market Reaction – OLMA
In the Feb 20 session, OLMA gained 1.13%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.5% during that session. Argus tracked a trough of -3.8% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Investor conferences | Neutral | +0.8% | Outlined participation in three February 2026 investor conferences. |
| Feb 03 | Inducement grants | Neutral | +1.9% | Granted options for 24,000 shares to two new employees under inducement plan. |
| Jan 30 | Executive departure | Negative | -0.3% | COO/CFO departure with CEO assuming interim principal financial officer role. |
| Jan 05 | Inducement grants | Neutral | -0.7% | Issued options for 223,500 shares to eight new employees at $25.28 exercise price. |
| Jan 05 | Conference presentation | Neutral | -0.7% | Announced presentation at J.P. Morgan Healthcare Conference with webcast access. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent corporate updates, including conferences and inducement grants, have produced modest, directionally consistent price moves.
Over the past several weeks, Olema has mainly reported corporate and investor-relations items. In January–February 2026, news included multiple inducement stock option grants, participation in several investor conferences, and the departure of the Chief Operating and Financial Officer with the CEO assuming interim financial duties. Price reactions were modest (generally within a few percent) and tended to align with the neutral-to-slightly-mixed tone of the releases. Today’s conference appearance fits this pattern of ongoing investor outreach rather than a new clinical or financial catalyst.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 2:30 p.m. ET.
A live webcast and recording of this presentation will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
